Source:http://linkedlifedata.com/resource/pubmed/id/15646070
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0017431,
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0030705,
umls-concept:C0042749,
umls-concept:C0080194,
umls-concept:C0087111,
umls-concept:C0181090,
umls-concept:C0301630,
umls-concept:C0302614,
umls-concept:C0392747,
umls-concept:C0871261,
umls-concept:C0887947,
umls-concept:C1516240,
umls-concept:C1704632,
umls-concept:C1706050,
umls-concept:C1706817,
umls-concept:C2911692
|
| pubmed:issue |
2 Suppl 1
|
| pubmed:dateCreated |
2005-1-13
|
| pubmed:abstractText |
The aim of this study was to evaluate outcome after a genotype guided change of therapy in 18 patients failing HAART. Patients were divided into two groups according to the response to therapy: immune responders (12 patients with immune recovery defined as having more than 100 CD4 cells compared to baseline value), and 6 failing patients (without immune recovery). At month 12 after genotype change of therapy a significant difference in the decrease of HIV-RNA viral load between the two groups of patients was detected (mean -1.95 and +0.04 log HIV-RNA copies/ml, p=0.04). One year after the change of therapy, all but one patients experienced a decrease in the replication capacity of HIV strains. Particularly, the HIV replication capacity of HIV strains decreased from 52% (range 14-98%) to 15.2% (range 0.1-74.5%). The HIV strains of patients failing HAART showed a progressive impaired replication capacity. In patients failing HAART the impaired replication capacity of HIV strains could justify the persistence of an immune recovery.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1121-7138
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
95-8
|
| pubmed:dateRevised |
2011-2-25
|
| pubmed:meshHeading |
pubmed-meshheading:15646070-Adult,
pubmed-meshheading:15646070-Anti-HIV Agents,
pubmed-meshheading:15646070-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15646070-CD4 Lymphocyte Count,
pubmed-meshheading:15646070-Drug Resistance, Viral,
pubmed-meshheading:15646070-Female,
pubmed-meshheading:15646070-Genotype,
pubmed-meshheading:15646070-HIV Infections,
pubmed-meshheading:15646070-HIV-1,
pubmed-meshheading:15646070-Humans,
pubmed-meshheading:15646070-Male,
pubmed-meshheading:15646070-Middle Aged,
pubmed-meshheading:15646070-RNA, Viral,
pubmed-meshheading:15646070-Viral Load,
pubmed-meshheading:15646070-Viremia,
pubmed-meshheading:15646070-Virus Replication
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.
|
| pubmed:affiliation |
Department of Public Health, University of Rome Tor Vergata, Rome.
|
| pubmed:publicationType |
Journal Article
|